文献速递类风湿关节炎

类风湿关节炎血清阳性与死亡率关联及改善病情抗风湿药治疗影响

Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-01-13

该真实世界研究纳入具有可评估ACPA和RF状态的类风湿关节炎患者,分析抗体阳性及滴度与死亡率的关系,并观察bDMARD与cDMARD暴露对上述关联的影响。结果显示ACPA/RF阳性及高滴度与死亡率升高独立相关,该关联在cDMARD暴露患者中持续存在,而在bDMARD暴露患者中未见差异。

要点

  • ACPA和RF阳性患者死亡率分别较阴性者升高48.0%和44.0%(P均<0.001)。
  • ACPA高滴度者死亡风险HR 1.60(95%CI 1.45-1.76),RF高滴度者HR 1.78(95%CI 1.66-1.91)。
  • 血清阳性与死亡率的关联在cDMARD暴露患者中持续,在bDMARD暴露患者中未见差异。

核心结论

  • ACPA/RF滴度升高与类风湿关节炎患者死亡率增加独立相关,该关联在cDMARD治疗患者中持续存在,但在bDMARD治疗患者中未观察到。

研究设计与样本

  • 基于2005-2016年行政索赔数据链接实验室结果的真实世界研究,纳入已确诊类风湿关节炎患者,按ACPA/RF阳性状态及抗体滴度分组,并区分bDMARD与cDMARD暴露亚组。
  • 共有53,849例患者具有可评估ACPA状态,79,926例具有可评估RF状态。
  • 采用粗死亡率/1000患者年、Kaplan-Meier曲线、校正Cox比例风险回归及倾向性评分匹配敏感性分析进行比较。

主要发现

  • ACPA阳性患者死亡率较阴性者升高48.0%(P<0.001),RF阳性患者死亡率较阴性者升高44.0%(P<0.001)。
  • 较高抗体滴度患者死亡率高于较低滴度者:ACPA HR 1.60(95%CI 1.45-1.76),RF HR 1.78(95%CI 1.66-1.91)。
  • 在cDMARD暴露患者中,血清阳性者HR高于血清阴性者;在bDMARD暴露患者中,死亡率按血清状态无差异。

关键数值与推荐

  • ACPA阳性较阴性死亡率升高48.0%(P<0.001);RF阳性较阴性死亡率升高44.0%(P<0.001)。
  • 高滴度ACPA与死亡率关联HR 1.60(95%CI 1.45-1.76);高滴度RF与死亡率关联HR 1.78(95%CI 1.66-1.91)。

临床怎么用

  • 对ACPA/RF阳性尤其高滴度类风湿关节炎患者,应关注死亡风险增高并加强共病管理与随访。
  • bDMARD暴露患者中未观察到血清状态与死亡率的关联,cDMARD暴露患者中关联持续,治疗选择时需考虑血清状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Seropositivity for anti-citrullinated protein antibody (ACPA)/rheumatoid factor (RF) in rheumatoid arthritis (RA) is associated with increased overall mortality; however, the association between antibody titers and mortality is not well established. Investigating relationships between antibody titers and mortality may clarify their role in RA pathogenesis. This study was undertaken to evaluate the association of antibody titers with mortality and its modification by disease-modifying antirheumatic drugs (DMARDs). METHODS: Eligible patients with established RA were identified through administrative claims data linked to laboratory results (2005-2016). Patients were categorized by positivity status for ACPA, RF, or both. Patients were further divided into groups by autoantibody titers. DMARD-exposed patients were categorized into biologic DMARD (bDMARD) and conventional DMARD (cDMARD) subcohorts. Crude mortality rates/1,000 patient-years and Kaplan-Meier curves were compared between antibody categories. Adjusted Cox proportional hazards regression and sensitivity (propensity-matched patients) analyses were conducted. RESULTS: Overall, 53,849 and 79,926 patients had evaluable ACPA and RF status, respectively. For both autoantibodies, mortality rates were significantly higher in seropositive versus seronegative patients (risk increase of 48.0% and 44.0% in ACPA- and RF-positive patients, respectively; P < 0.001 each). Mortality rates were greatest in patients with higher versus lower autoantibody titers (ACPA hazard ratio [HR] 1.60 [95% confidence interval (95% CI]) 1.45-1.76]; RF HR 1.78 [95% CI 1.66-1.91]). In cDMARD-exposed patients, HRs were higher in seropositive versus seronegative cohorts; in bDMARD-exposed patients, there was no difference in mortality by serostatus. CONCLUSION: Elevated ACPA/RF titers were independently associated with increased mortality among patients with RA and persisted in patients treated with cDMARDs but not with bDMARDs.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Alemao E, Bao Y, Weinblatt ME, et al. Association of Seropositivity and Mortality in Rheumatoid Arthritis and the Impact of Treatment With Disease-Modifying Antirheumatic Drugs: Results From a Real-World Study. Arthritis Care Res (Hoboken). 2020. PMID: 31529682. doi:10.1002/acr.24071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。